S. Paniga

Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects.

A. D'Angelo, C. Tinelli, S. Del Prato, 2007, Diabetes & metabolism.

Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.

A. D'Angelo, C. Tinelli, G. Derosa, 2006, Endothelium : journal of endothelial cell research.

Matrix Metalloproteinase-2, -9 and Tissue Inhibitor Metalloproteinase-1 in Patients with Hypertension Before and After Doxazosin Therapy

A. D'Angelo, C. Tinelli, R. Fogari, 2006 .

Effect of Doxazosin on C-Reactive Protein Plasma Levels and on Nitric Oxide in Patients With Hypertension

A. D'Angelo, C. Tinelli, R. Fogari, 2006, Journal of cardiovascular pharmacology.

Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome

G. Derosa, A. Cicero, S. Salvadeo, 2006, The Journal of international medical research.

Metformin–pioglitazone and metformin–rosiglitazone effects on non‐conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome

A. D'Angelo, G. Derosa, S. Salvadeo, 2006, Journal of clinical pharmacy and therapeutics.

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin

A. D'Angelo, G. Derosa, A. Cicero, 2007, Internal medicine journal.